Check out our most popular compounded medications! Get Started
Chlorpheniramine Maleate 12 mg Slow Release Capsules, formulated with Methocel E4M, are designed to gradually release the active ingredient over an extended period. This controlled-release mechanism offers sustained therapeutic effects, reduces dosing frequency, and improves patient compliance. These capsules are used to treat conditions such as Allergic Rhinitis, Urticaria, Pruritus, Asthma, and Angioedema.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
This formulation is specifically engineered to gradually release the active ingredient, chlorpheniramine maleate, over an extended period of time, ensuring a sustained therapeutic effect.
These capsules are formulated with Methocel E4M, a type of controlled-release polymer. This innovative technology allows for the encapsulated medication to be released gradually, offering a prolonged therapeutic effect. This slow release mechanism reduces the need for frequent dosing and improves patient compliance, particularly beneficial for medications requiring a controlled and extended release profile.
Chlorpheniramine Maleate 12 mg Slow Release Capsules are indicated for the treatment of allergic rhinitis, urticaria, and other allergic conditions. The encapsulated form of these capsules makes them easy to take and store, while the slow release of the active ingredient ensures better symptom control over a longer period of time.
If you have any questions about this formulation or any other compounding services we offer, we encourage you to reach out to us. We are here to assist you with your healthcare needs.
Chlorpheniramine Maleate 12 mg Slow Release Capsules are a compounded formulation designed for the treatment of various allergic reactions such as allergic rhinitis, urticaria, and other hypersensitivity responses. The capsules are formulated with Methocel E4M, a type of controlled-release polymer, which ensures the gradual release of the active ingredient over an extended period. This slow-release mechanism offers sustained therapeutic effects, reduces the frequency of dosing, and improves patient compliance, particularly for medications requiring a controlled and prolonged release profile.
It is important for patients to be aware that Chlorpheniramine Maleate 12 mg Slow Release Capsules may interact with other medications. These include anticholinergics, antihistamines, and monoamine oxidase inhibitors (MAOIs). Therefore, patients should inform their healthcare provider of all medications they are currently taking before starting this treatment. Potential side effects of Chlorpheniramine Maleate 12 mg Slow Release Capsules include drowsiness, dry mouth, and dizziness. As such, patients are advised not to drive or operate machinery until they understand how this medication affects them. For any questions or concerns regarding the use of Chlorpheniramine Maleate 12 mg Slow Release Capsules, patients are encouraged to reach out to their healthcare provider.
Chlorpheniramine Maleate 12 mg Slow Release Capsules are a potent formulation designed to alleviate symptoms associated with allergies, hay fever, and the common cold. The active ingredient, chlorpheniramine maleate, is a powerful antihistamine that functions by inhibiting the action of histamine, a substance in the body that triggers allergic symptoms. The unique slow-release formulation of these capsules, made possible by the use of Methocel E4M, a controlled-release polymer, ensures a gradual and consistent release of the medication over an extended period. This slow-release mechanism offers sustained therapeutic effects, thereby reducing the frequency of dosing and enhancing patient compliance, particularly for medications that necessitate a controlled and prolonged release profile.
The recommended dosage for adults and children over 12 years of age is one capsule every 12 hours. For children under 12 years of age, the appropriate dosage should be determined by a healthcare provider. It's important to note that common side effects of this medication may include drowsiness, dry mouth, and dizziness. If any of these side effects are experienced, it is advised to contact a healthcare provider immediately. For any further queries or concerns regarding Chlorpheniramine Maleate 12 mg Slow Release Capsules, please do not hesitate to reach out.
Chlorpheniramine Maleate 12 mg Slow Release Capsules is a medication that is encapsulated in a controlled-release polymer, Methocel E4M. This formulation is designed to gradually release the active ingredient over an extended period of time.
Methocel E4M is a type of controlled-release polymer that is used to encapsulate the medication. It is designed to gradually release the active ingredient over an extended period of time, offering sustained therapeutic effects and improved patient compliance.
The benefits of using this formulation include sustained therapeutic effects, reduced dosing frequency, and improved patient compliance. This is particularly beneficial for medications requiring a controlled and prolonged release profile.
The slow release mechanism works by gradually releasing the active ingredient over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M, which encapsulates the medication.
'Improved patient compliance' means that patients are more likely to take their medication as prescribed. This is because the slow release formulation reduces the frequency of dosing, making it easier for patients to adhere to their medication regimen.
'Sustained therapeutic effects' means that the medication continues to have its intended therapeutic effect over an extended period of time. This is due to the slow release of the active ingredient from the capsule.
'Reduced dosing frequency' means that patients need to take their medication less often. This is because the slow release formulation allows the active ingredient to be gradually released over an extended period of time.
Yes, Chlorpheniramine Maleate 12 mg Slow Release Capsules is safe to use as prescribed by a healthcare professional. However, like all medications, it may have potential side effects and should be used under the supervision of a healthcare provider.
Chlorpheniramine Maleate 12 mg Slow Release Capsules should be used as prescribed by a healthcare professional. It may not be suitable for everyone, and its use should be based on a patient's specific medical condition and response to treatment.
If you miss a dose of Chlorpheniramine Maleate 12 mg Slow Release Capsules, take it as soon as you remember. However, if it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
